Investor Days Thuringia 2021
On June 15 and 16, 2021, the Stiftung für Technologie, Innovation und Forschung Thüringen (STIFT) and bm-t beteiligungsmanagement thüringen gmbh (bm|t) organized the “Investor Days Thuringia” (IDT) in Erfurt – in digital format due to the corona pandemic.
We were happy that Dynamic42 received one of the coveted lecture places. A total of 23 start-ups and 13 growth companies presented their business concepts on the digital IDT pitch stage on 15 June. Ahead 67 projects from Germany, Austria, Israel, Italy, New Zealand, Spain, South Africa, the Czech Republic, Hungary, and Uruguay applied.
Our managing directors Dr. Martin Raasch and Dr. Knut Rennert presented Dynamic42 GmbH in a five-minute pitch in the category “Growth Companies”. In addition to the Dynamic42 organ-on-chip models and current market figures, Knut and Martin talked about the company’s goals and outlined the strategic positioning of the coming years.
On June 15, we were also represented with our digital booth in the Innovation Arena. Here we were able to establish further contacts with investors and multipliers and initiate the first potential cooperation.
On the second day, we were able to intensively exchange and network with representatives of the local economy, start-up scene and contact persons for funding instruments in a round-table format.
We would like to thank the organizers of the “Investor Days” for the successful event. This event has brought us plenty positive feedback and make new contacts with investors possible.
About the Investor Days Thuringia 2021
From June 15 to 16, innovation-driven start-ups and growth companies met with national and international industries and investors. As part of this online event, around 600 participants exchanged their view on latest technologies and trends from various industries. The whole program was broadcast live from the Erfurt Multifunctional Arena.
Picture: Mobile Event App
More interesting articles:
Blog, Disease-Modeling, Gut-on-Chip, Infection-Modeling
When butyrate drops, the gut loses more than a metabolite – it loses resilience
In this new study by Manuel Allwang, Maximilian Wipplinger, and Parastoo Akbarimoghaddam and colleagues, published in Small, the authors show why that loss may be especially important when inflamed tissue is challenged by the opportunistic fungus Candida albicans.
Read MoreBlog, Drug Development, Liver-on-Chip
Evaluation of a liver-chip model for clearance prediction
In this new publication led by scientists at Novartis and the University of Tübingen, the authors take a deep, engineering level look at the performance of a microphysiological liver on chip model for predicting human hepatic clearance, a central parameter in preclinical drug development.
Read MoreBlog, Gut-on-Chip, Infection-Modeling
Modeling Clostridioides difficile toxin pathogenesis and antiserum protection
In this new study from Jena University Hospital and the Paul-Ehrlich-Institute, the authors show that how we model Clostridioides difficile toxin exposure fundamentally shapes our ability to understand epithelial damage, immune activation, and therapeutic protection.
Read More